OBJECTIVE: The goal of this study was to determine the effect of a genetic variant in the organic cation transporter 2 (OCT2), OCT2-808G/T, which results in an amino acid change, A270S, on the pharmacokinetics of the antidiabetic drug, metformin. METHODS: The uptake of metformin was performed in stably transfected HEK-293 cells expressing the empty vector (MOCK), the reference OCT2-808G, and the variant OCT2-808T. Healthy individuals with known OCT2 genotypes [14 homozygous for the OCT2 reference allele (808G/G) and nine heterozygous for the variant allele (808G/T, *3D)] were recruited to this study. Metformin concentrations in plasma and urine were measured by liquid chromatography-tandem mass spectrometry method. Creatinine levels were also measured in plasma and urine. Pharmacokinetic parameters were evaluated for both the groups. RESULTS: We observed that in HEK-293 stably transfected cells, OCT2-808T had a greater capacity to transport metformin than did the reference OCT2. Metformin pharmacokinetics was characterized in 23 healthy volunteers of Caucasian and African-American ancestries. We observed that the renal clearance (CL(R)) and the net secretion (SrCL(R)) of metformin were significantly different between the volunteers heterozygous for the variant allele (808G/T), and the volunteers homozygous for the reference allele (808G/G) (P<0.005). Multivariate analysis revealed that OCT2 genotype was a significant predictor of CL(R) and SrCL(R) of metformin (P<0.01). CONCLUSION: We conclude that genetic variation in OCT2 plays an important role in the CL(R) and SrCL(R) of metformin in healthy volunteers.
OBJECTIVE: The goal of this study was to determine the effect of a genetic variant in the organic cation transporter 2 (OCT2), OCT2-808G/T, which results in an amino acid change, A270S, on the pharmacokinetics of the antidiabetic drug, metformin. METHODS: The uptake of metformin was performed in stably transfected HEK-293 cells expressing the empty vector (MOCK), the reference OCT2-808G, and the variant OCT2-808T. Healthy individuals with known OCT2 genotypes [14 homozygous for the OCT2 reference allele (808G/G) and nine heterozygous for the variant allele (808G/T, *3D)] were recruited to this study. Metformin concentrations in plasma and urine were measured by liquid chromatography-tandem mass spectrometry method. Creatinine levels were also measured in plasma and urine. Pharmacokinetic parameters were evaluated for both the groups. RESULTS: We observed that in HEK-293 stably transfected cells, OCT2-808T had a greater capacity to transport metformin than did the reference OCT2. Metformin pharmacokinetics was characterized in 23 healthy volunteers of Caucasian and African-American ancestries. We observed that the renal clearance (CL(R)) and the net secretion (SrCL(R)) of metformin were significantly different between the volunteers heterozygous for the variant allele (808G/T), and the volunteers homozygous for the reference allele (808G/G) (P<0.005). Multivariate analysis revealed that OCT2 genotype was a significant predictor of CL(R) and SrCL(R) of metformin (P<0.01). CONCLUSION: We conclude that genetic variation in OCT2 plays an important role in the CL(R) and SrCL(R) of metformin in healthy volunteers.
Authors: C R Sirtori; G Franceschini; M Galli-Kienle; G Cighetti; G Galli; A Bondioli; F Conti Journal: Clin Pharmacol Ther Date: 1978-12 Impact factor: 6.875
Authors: J H Choi; S W Yee; A H Ramirez; K M Morrissey; G H Jang; P J Joski; J A Mefford; S E Hesselson; A Schlessinger; G Jenkins; R A Castro; S J Johns; D Stryke; A Sali; T E Ferrin; J S Witte; P-Y Kwok; D M Roden; R A Wilke; C A McCarty; R L Davis; K M Giacomini Journal: Clin Pharmacol Ther Date: 2011-09-28 Impact factor: 6.875
Authors: M A Daniels; C Kan; D M Willmes; K Ismail; F Pistrosch; D Hopkins; G Mingrone; S R Bornstein; A L Birkenfeld Journal: Pharmacogenomics J Date: 2016-07-19 Impact factor: 3.550
Authors: Michael Z Liao; Shannon K Flood Nichols; Mahmoud Ahmed; Shannon Clark; Gary D Hankins; Steve Caritis; Raman Venkataramanan; David Haas; Sara K Quinney; Laura S Haneline; Alan T Tita; Tracy Manuck; Joanne Wang; Kenneth E Thummel; Linda Morris Brown; Zhaoxia Ren; Thomas R Easterling; Mary F Hebert Journal: Drug Metab Dispos Date: 2020-01-24 Impact factor: 3.922
Authors: Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang Journal: Nat Rev Drug Discov Date: 2010-03 Impact factor: 84.694
Authors: So-Youn Shin; Ann-Kristin Petersen; Nicole Soranzo; Christian Gieger; Karsten Suhre; Robert P Mohney; David Meredith; Brigitte Wägele; Elisabeth Altmaier; Panos Deloukas; Jeanette Erdmann; Elin Grundberg; Christopher J Hammond; Martin Hrabé de Angelis; Gabi Kastenmüller; Anna Köttgen; Florian Kronenberg; Massimo Mangino; Christa Meisinger; Thomas Meitinger; Hans-Werner Mewes; Michael V Milburn; Cornelia Prehn; Johannes Raffler; Janina S Ried; Werner Römisch-Margl; Nilesh J Samani; Kerrin S Small; H-Erich Wichmann; Guangju Zhai; Thomas Illig; Tim D Spector; Jerzy Adamski Journal: Nature Date: 2011-08-31 Impact factor: 49.962
Authors: Faisal E Al Jofi; Tao Ma; Dong Guo; Monica P Schneider; Yan Shu; Hockin H K Xu; Abraham Schneider Journal: Cytotherapy Date: 2018-03-16 Impact factor: 5.414